Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783549 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT00783549 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 76 participants.
The verdict
NCT00783549, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This study is the first study in humans to assess the safety and tolerability of various doses of GSK1292263 alone, and taken with sitigliptan.
Interventions
- DRUG an undetermined dose of GSK1292263
- DRUG ascending dose of GSK1292263
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2008-09-04 |
| Est. Completion | 2009-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00783549
The ClinicalTrials.gov registry entry for NCT00783549 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which an undetermined dose of GSK1292263 is the first listed.
NCT00783549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00783549 about?
NCT00783549 is a clinical study titled "A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.". This study is the first study in humans to assess the safety and tolerability of various doses of GSK1292263 alone, and taken with sitigliptan.
What is the current status of trial NCT00783549?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2008-09-04. Estimated completion is 2009-03-31.
What interventions are being tested in trial NCT00783549?
The interventions under investigation include: an undetermined dose of GSK1292263 (DRUG), ascending dose of GSK1292263 (DRUG).
Who is sponsoring clinical trial NCT00783549?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.